MONITORFEDGLP-1 CompoundingNov 5, 2025

FDA recall (Class II): Semaglutide Injection, 10 mg/4 mL (2.5 mg/mL), 4mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Je…

FDA recalls Semaglutide injection over sterility issues; take action!

What changed & why it matters

Med Spa Radar recorded an FDA enforcement action at the federal level, dated November 5, 2025, in the GLP-1 Compounding category, naming Semaglutide.

A recall of Semaglutide is a supply-chain event, not a rule that might change: if the pharmacy or outsourcing facility a med spa sources from distributed an affected lot, it is a patient-safety and liability exposure today. Recalls are the clearest signal that a supplier a practice may already use has a quality problem on record with the FDA.

Type
FDA Enforcement
Jurisdiction
Federal
Category
GLP-1 Compounding
Substance
Semaglutide
Recorded
November 5, 2025

What this means for your specific practice — the exact step to take, the deadline to calendar, or the supplier detail to check — is in the member "what to do" below. This page is the free record of what changed and why it matters.

What to do

Free weekly Brief

Get the changes that matter in plain English, every week — and be alerted when the rules move. No charge.

Members get the full “what to do” on every alert — in real time, for your states. Become a member →

FDA Enforcement · primary source ↗

Related alerts

Monitoring, not legal advice.